High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

Fumiaki Isohashi; Yasuo Yoshioka; Masahiko Koizumi; Koji Konishi; Iori Sumida; Yutaka Takahashi; Toshiyuki Ogata; Ken ichirou Morishige; Takayuki Enomoto; Yoshifumi Kawaguchi; Tadayuki Kotsuma; Kana Adachi; Shoichi Fukuda; Yuichi Akino; Takehiro Inoue

doi:10.1016/j.brachy.2008.12.002

High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

Fumiaki Isohashi, Yasuo Yoshioka, Masahiko Koizumi, Koji Konishi, Iori Sumida, Yutaka Takahashi, Toshiyuki Ogata, Ken ichirou Morishige, Takayuki Enomoto, Yoshifumi Kawaguchi, Tadayuki Kotsuma, Kana Adachi, Shoichi Fukuda, Yuichi Akino, Takehiro Inoue

Office of Academic Clinical Affairs

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30 Gy/15 fractions was followed by HDR-ISBT of 30 Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20 Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.

Original language	English (US)
Pages (from-to)	234-239
Number of pages	6
Journal	Brachytherapy
Volume	8
Issue number	2
DOIs	https://doi.org/10.1016/j.brachy.2008.12.002
State	Published - Apr 2009

Keywords

Brachytherapy
Cervical carcinoma
High dose rate
Interstitial
Previously untreated

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.brachy.2008.12.002

OpenUrl availability

Full text

Cite this

@article{9b8ac246176241f2bd6b6c5313fce7fb,

title = "High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma",

abstract = "Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30 Gy/15 fractions was followed by HDR-ISBT of 30 Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20 Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.",

keywords = "Brachytherapy, Cervical carcinoma, High dose rate, Interstitial, Previously untreated",

author = "Fumiaki Isohashi and Yasuo Yoshioka and Masahiko Koizumi and Koji Konishi and Iori Sumida and Yutaka Takahashi and Toshiyuki Ogata and Morishige, {Ken ichirou} and Takayuki Enomoto and Yoshifumi Kawaguchi and Tadayuki Kotsuma and Kana Adachi and Shoichi Fukuda and Yuichi Akino and Takehiro Inoue",

year = "2009",

month = apr,

doi = "10.1016/j.brachy.2008.12.002",

language = "English (US)",

volume = "8",

pages = "234--239",

journal = "Brachytherapy",

issn = "1538-4721",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

AU - Isohashi, Fumiaki

AU - Yoshioka, Yasuo

AU - Koizumi, Masahiko

AU - Konishi, Koji

AU - Sumida, Iori

AU - Takahashi, Yutaka

AU - Ogata, Toshiyuki

AU - Morishige, Ken ichirou

AU - Enomoto, Takayuki

AU - Kawaguchi, Yoshifumi

AU - Kotsuma, Tadayuki

AU - Adachi, Kana

AU - Fukuda, Shoichi

AU - Akino, Yuichi

AU - Inoue, Takehiro

PY - 2009/4

Y1 - 2009/4

N2 - Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30 Gy/15 fractions was followed by HDR-ISBT of 30 Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20 Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.

AB - Purpose: The aim of the study was to evaluate the results of high-dose-rate interstitial brachytherapy (HDR-ISBT) for patients with advanced cervical carcinoma in which intracavitary radiation therapy may result in a suboptimal dose distribution. Methods and Materials: Between 1995 and 2005, 25 patients of median age 64 years were treated with external beam radiation therapy and HDR-ISBT. The International Federation of Gynecology and Obstetrics stages of the patients were I (4%), II (16%), III (68%), and IVA (12%). Whole pelvic irradiation of 30 Gy/15 fractions was followed by HDR-ISBT of 30 Gy/5 fractions/3 days. Subsequently, additional pelvic external beam radiation therapy of 20 Gy/10 fractions was delivered with a midline block. The median followup period was 55 months. Results: The actuarial 5-year progression-free survival and overall survival rates for all cases were 42% and 54%, respectively. For the 17 patients with a Stage III tumor, the 5-year local control and overall survival rates were 73% and 51%, respectively. Two patients (8%) developed late toxicities of Grade 3. Conclusions: A high rate of pelvic control and survival with acceptable level of late toxicities were obtained for patients with advanced cervical carcinoma treated with HDR-ISBT.

KW - Brachytherapy

KW - Cervical carcinoma

KW - High dose rate

KW - Interstitial

KW - Previously untreated

UR - http://www.scopus.com/inward/record.url?scp=67349083254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349083254&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2008.12.002

DO - 10.1016/j.brachy.2008.12.002

M3 - Article

C2 - 19213610

AN - SCOPUS:67349083254

SN - 1538-4721

VL - 8

SP - 234

EP - 239

JO - Brachytherapy

JF - Brachytherapy

IS - 2

ER -

High-dose-rate interstitial brachytherapy for previously untreated cervical carcinoma

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this